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Purpose: To assess the value of hepatobiliary phase
gadoxetic acid (EOB)-enhanced magnetic resonance imag-
ing (MRI) for the diagnosis of early stage hepatocellular
carcinoma (HCC) (<3 cm) compared to triple-phase
dynamic multidetector computed tomography (MDCT).
Materials and Methods: In all, 52 patients with 60
pathologically proven HCCs underwent both EOB-
enhanced MRI and triple-phase dynamic MDCT. Two radi-
ologists independently and blindly reviewed three image
sets: 1) MDCT, 2) dynamic MRI (unenhanced and EOB-
enhanced dynamic MR images), and 3) combined MRI
(dynamic MRI þ hepatobiliary phase images) using a five-
point rating scale on a lesion-by-lesion basis. Receiver
operating characteristics (ROC) analysis was performed,
and sensitivity and specificity were calculated.
Results: The area under the ROC curve (Az) of dynamic
MRI was equivalent to that of MDCT for both readers. For
both readers, Az and sensitivity of combined MRI for
smaller lesions (<1.5 cm) were significantly higher than
that of dynamic MRI and MDCT (P < 0.0166). The major-
ity of false-negative nodules on dynamic MRI or MDCT
(75% and 62%, respectively) were due to a lack of identi-
fied washout findings.
Conclusion: Hepatobiliary phase images can increase the
value of EOB-enhanced MRI in the diagnosis of early
stage HCC. The sensitivity and accuracy were signifi-
cantly superior to MDCT for the diagnosis of lesions less
than 1.5 cm.
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HEPATOCELLULAR CARCINOMA (HCC) is the sixth
most common cancer worldwide and the third most
frequent cause of cancer death (1). HCC is the main
cause of death among cirrhotic patients and the inci-
dence of HCC is predicted to increase in the next two
decades (2). The diagnosis of early stage HCC, which
can be curable by partial hepatic resection, liver
transplantation, or locoregional therapies, is crucial
during the follow-up of high-risk patients. For
instance, early stage of the Barcelona-Clinic-Liver-
Cancer (BCLC) staging system or the Milan criteria
include patients with fewer than three nodules less
than 3 cm in size or a solitary lesion less than 5 cm
(3,4). Thus, the earlier detection of HCC (at least less
than 3 cm) by each imaging modality is a keystone in
the risk group patients. Both multidetector computed
tomography (MDCT) and magnetic resonance imaging
(MRI) play an important role in the accurate staging of
HCC in cirrhotic patients (5–7). Among a variety of
commercially available liver MR contrast agents, the
newly introduced contrast agent gadoxetic acid (EOB)
has theoretical advantages over extracellular agents.
Similar to extracellular contrast agents, EOB allows
for dynamic perfusion imaging to evaluate tumor vas-
cularity. However, since it is also taken up by hepato-
cytes, it also allows for liver-specific imaging (hepato-
biliary phase images) (8). The higher T1 relaxivity of
EOB in human blood due to its weak protein binding
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(10%) could contribute to stronger enhancement on
arterial phase images. The specific uptake of EOB in
functioning hepatocytes on hepatobiliary phase
images is another factor that may increase lesion-to-
liver contrast and the detectability of small lesions
(9,10). As the American Association for the Study of
Liver Diseases (AASLD) and the European Association
for the Study of the Liver (EASL) indicate (11,12), the
diagnosis of HCC using extracellular agents is based
mainly on assessment of tumor vascularity: hyperen-
hancement in the arterial phase followed by rapid
washout in portal venous or equilibrium phase.
Although these criteria have been established for the
diagnosis of HCC, they have some limitations because
the vascularity may vary depending on the histological
grading of HCC, whereas technical aspects (hardware,
injection methods, etc.) could influence sensitivity of
the arterial enhancement. EOB is not only an excel-
lent extracellular agent providing information on tu-
mor vascularity, but it also has a hepatocyte-specific
property, which could aid in the diagnosis of HCC.
Recent reports indicated similar or superior diagnostic
performance of EOB-enhanced MRI compared to
dynamic MDCT (13–18) and hepatobiliary phase
images provided modest improvement in the diagnosis
of HCC (16). However, to the best of our knowledge,
there have been some comparative studies between
MDCT imaging and gadolinium (Gd)-EOB-DTPA-
enhanced MRI for the diagnosis of HCC and few stud-
ies assessing the usefulness of hepatobiliary phase
images adding Gd-EOB-DTPA-enhanced MRI for com-
parison with MDCT imaging (18). The purpose of this
study was therefore to evaluate the added value of
hepatobiliary phase EOB-enhanced MRI for the diag-
nosis of early stage HCC compared to triple-phase
dynamic MDCT.
MATERIALS AND METHODS
This study complied with the principles of the Decla-
ration of Helsinki and subsequent amendments (19).
Our Institutional Review Board approved this study
(EOB has been approved for clinical use since Novem-
ber 2006 in Italy and the indication was according to
the label) and written informed consent was waived.
All data and information derived from and pertaining
to the study were under the exclusive control of the
investigating radiologists.
Patient Population
From January 2008 to July 2009 we retrospectively
reviewed our hospital reporting database of both ab-
dominal CT and MRI examinations in patients with
suspected HCC. We found 176 consecutive patients
suspected of having HCC. Among these patients, 46
patients were excluded from the study because of a
lack of satisfactory confirmation (ie, if both pathologi-
cal proof and sufficient follow-up examinations were
not available). Fifty-five patients were considered
ineligible for the study because of 1) a long interval
between MDCT and MRI (more than 21 days) (n ¼ 26);
2) the presence of more than 10 HCC lesions (n ¼ 18);
or 3) inadequate MDCT examination (n ¼ 6) (extrava-
sation of contrast agent or equipment failure) or MRI
examination (n ¼ 5) (nondiagnostic image quality due
to severe motion artifacts).
Finally, 75 patients (60 men and 15 women; age
range 42–67 years; mean age 54.7 years) with a total
of 86 nodules were enrolled in this study. Clinical in-
formation of the patients and characteristics of the
HCC lesions are summarized in Table 1. Among the
86 nodules, 60 nodules were HCCs, 10 nodules were
hemangiomas, and the remaining 16 nodules were
arterioportal (A-P) shunts. In all, 38 patients had only
HCC, 14 had HCC accompanied with hemangioma or
A-P shunt, and seven had only hemangioma or A-P
shunt. The diagnosis of all 60 HCC nodules was
achieved based on pathologic specimens: surgical
resection (n ¼ 19) or fine needle biopsy (n ¼ 41). Out
of 60 pathologically proven HCCs, 10 were well-differ-
entiated, 28 were moderately differentiated, and 22
were poorly differentiated. The 36 benign lesions were
confirmed by the fact that these lesions did not show
any interval change in size at follow-up CT or MRI for
more than 6 months and/or typical imaging findings
at multimodality examinations, including contrast-
enhanced ultrasound (US) and follow-up studies. The
mean diameter 6 standard deviation of HCC was 17.4
6 6.53 mm (range, 5–28 mm), and 12 (20%) HCCs
had a diameter of 10 mm or less, as measured on
those images on which the lesions were most clearly
visualized (eg, arterial or hepatobiliary phases) on
reading sessions. The 21 HCCs were located in the
left lobe (S1–4) and the remaining 39 HCCs were
Table 1
Clinical information of the 75 patients and characteristics
of 60 HCC lesions
Age range (mean age) 42-67 years (54.7 years)
Sex (M/F) 60/15
Diagnosis of the lesions
(n ¼ 86)
60 HCC, 10 hemangioma,
16 A-P shunt
Characteristics of 60
HCCs (52 pts)
a. Mean size 6 SD 17.4 6 6.53 mm
(12 HCCs 5 10 mm)
b. Location 39 in right lobe
21 in left lobe
c. Histopathology 10 well-differentiated
28 moderately-differentiated
22 poorly-differentiated
Background liver (n ¼ 75 pts) 54 LC, 4 CH, 3 steatosis,
4 normal
Cause of LC 23 HCV
14 HBV
4 HCVþHBV
10 Alcohol
3 cryptogenic
Child-Pugh classification
48 Child A
5 Child B
1 Child C
Note: HCC: Hepatocellular carcinoma; LC: Liver cirrhosis; CH:
Chronic hepatitis.
HBV: Hepatitis B virus; HCV: Hepatitis C virus.
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located in the right lobe (S5–8). Twenty-three patients
had hepatitis C virus (HCV)-induced liver cirrhosis,
18 patients had liver cirrhosis (n ¼ 14) or chronic
hepatitis (n ¼ 4) associated with hepatitis B virus
(HBV), four patients had HCV and HBV-induced liver
cirrhosis, 10 patients had alcohol-related cirrhosis
(four combined with HCV and two combined with
HBV), and three patients had cryptogenic liver cirrho-
sis. Seventeen patients had a noncirrhotic liver (14
normal livers and three steatotic livers). The severity
of liver cirrhosis was based on the Child-Pugh classifi-
cation: 48 patients were classified as Child class A, 5
patients as Child class B, and the remaining patient
as Child class C. The time interval between MDCT
and MRI ranged between 3 and 20 days (mean, 9.3
days).
MDCT Examination
CT examinations were conducted using an MDCT
scanner (Sensation 16, Siemens Medical Systems,
Erlangen, Germany) with 16 detector rows. The
images were obtained in the craniocaudal direction
with 0.75  16 beam collimation. The scanning pa-
rameters were 120 kVp, 150 mAs, 5-mm slice thick-
ness with a reconstruction interval of 3.0 mm, table
speed of 24 mm (pitch 1.5:1), 0.5-second gantry rota-
tion time, volumetric CT dose index of 10.7 mGy, and
a single breath-hold helical acquisition of 7–9 seconds
depending on the liver volume of each patient. All
patients received intravenous nonionic contrast me-
dium (Ultravist 370, Bayer Schering Pharma, Berlin,
Germany) containing a high concentration of iodine
(370 mg of iodine per kg). The volume of delivered
contrast medium was determined according to the
body weight of each patient (1.8 mL/kg of body
weight). The contrast medium was warmed to
decrease its viscosity and administered intravenously
at 4 mL/sec with a mechanical power injector (Mis-
souri, Ulrich, Ulm, Germany), followed by a 40-mL sa-
line flash through a 20G catheter inserted into an
antecubital vein. After precontrast imaging, CT imag-
ing was performed during dominant hepatic arterial,
portal venous, and late phases at 26–30 seconds
(mean 28.4 sec), 70 seconds, and 180 seconds,
respectively, after the administration of the contrast
medium. The time-to-peak aortic enhancement was
evaluated by an automatic bolus-tracking technique
with automated scan-triggering software (CARE Bolus
CT; Siemens Medical Systems) to determine the opti-
mal scanning delay for the arterial phase in all
patients. The single level monitoring low dose scan-
ning (20 mAs) was initiated 5 seconds after contrast
injection and arterial phase scanning was started
automatically 15 seconds after the trigger threshold
(increase of 120 HU) had been reached at the level of
the suprarenal abdominal aorta.
MR Examination
MRI was performed with a 1.5-T scanner (Avanto, Sie-
mens Medical Systems) equipped with an 18-channel
system (maximum gradient strength of 45 mT/m,
peak slew rate of 200 mT/m/msec) and a 12-element
phased-array surface body coil. All MR images were
acquired in the transverse plane covering the upper
abdomen during end-expiratory breath-hold or with
respiratory triggering. Presaturation pulses were
applied above and below the imaging volume to
reduce flow artifacts from vessels. All MR images were
acquired using mSENSE (reduction factor ¼ 2) to
reduce scanning time. Before administration of the
contrast agent, dual-echo T1-weighted (T1W) gradi-
ent-echo (GRE) sequence (repetition time/echo times
[TR/TEs], 131/2.6/5 out phase / in phase; flip angle,
70; matrix size, 166  256; bandwidth, 260 Hz/pixel;
field of view [FOV], 38–50 cm) with breath-hold and a
5-mm section thickness, respiratory triggered T2-
weighted (T2W) turbo spin-echo (TSE) sequence (TR/
TE, 1600/79; flip angle, 150; matrix size, 166  256;
bandwidth, 260 Hz/pixel; FOV, 38–50 cm), without
fat suppression and a 5-mm section thickness were
obtained. After these precontrast images, a T1W 3D
GRE fat-saturated volumetric interpolated breath-
hold examination sequence (VIBE; Siemens) (TR/TE
5.2/2.5; flip angle, 10; matrix size, 166  320; band-
width, 250 Hz/pixel; FOV, 38–50 cm; voxel size, 1.72
[read]  1.19 (phase)  4.00 mm [slice]) with a 4-mm
section thickness was acquired before administration
of the contrast agent and during the arterial phase at
25–37 seconds (mean delay time, 30.5 sec), during
the portal venous phase at 70 seconds, during the
equilibrium phase at 180 seconds, and during the
hepatobiliary phase at 5 minutes, 10 minutes, 15
minutes, and 20 minutes, respectively. We also used
the MR fluoroscopic bolus detection technique (CARE
Bolus; Siemens) to adjust optimal scan delay timing
for arterial phase imaging. In all patients, 0.025
mmol/kg body weight of EOB (Primovist, Bayer Sche-
ring Pharma) was administered at 1 mL/sec intrave-
nously as recommended with a mechanical power in-
jector (MedRad Spectris Solaris EP) through a 20G
catheter inserted into an antecubital vein, followed by
a 20-mL saline flush at the same injection rate (20).
Between 5 minutes and 20 minutes after administra-
tion of the contrast medium, respiratory triggered
T2W-TSE sequence with fat suppression and naviga-
tor triggered diffusion-weighted echo planar sequence
(DWI) (TR/TE of 2000/71 msec; section thickness/
gap, 6/1.2 mm; FOV, 32–45 cm; matrix size, 77 
192; echo train length, 77; bandwidth, 628 Hz/pixel;
spectral attenuated inversion recovery [SPAIR] fat
suppression; number of excitations, 2; tridirectional
motion probing gradients with b-values of 50, 400,
and 800 s/mm2; image acquisition time, 4–5 minutes)
were obtained.
Image Analysis
Two abdominal radiologists with 21 and 15 years of
experience, respectively, in the interpretation of he-
patic MR images independently, blindly, and ran-
domly evaluated three imaging modalities: 1) triphase
dynamic MDCT (arterial, portal, and equilibrium
phases); 2) dynamic MRI: unenhanced (precontrast
T1WI and T2WI) and EOB-enhanced dynamic images
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(arterial, portal, and late phases); 3) combined MRI:
dynamic þ hepatobiliary phase images on a lesion-by-
lesion basis. The readers were aware of the image
phase and that all patients had cirrhosis and sus-
pected HCC, but were unaware of the results of tumor
histopathology, US findings, tumor marker levels (eg,
AFP, PIVKA II), and the opinions of other readers. All
images were assessed on a local picture archiving and
communication system monitor (iSite Radiology, Phi-
lips Healthcare). The images were adjusted to an opti-
mal window setting in each case and the readers eval-
uated them in the same conditions. To minimize
recognition bias, reading sessions occurred at 3-week
intervals. For objectivity and reproducibility, the read-
ers were instructed to use the following criteria for
supporting the diagnosis of HCC: i) intense arterial
enhancement and hypoattenuation or hypointensity
compared with surrounding liver parenchyma (wash-
out) during portal venous or equilibrium/late phases;
ii) peripheral rim enhancement during portal venous or
equilibrium/late phases; and iii) intense arterial
enhancement and hypointensity during hepatobiliary
phase (12). Suggestive criteria for the diagnosis of HCC
included a) moderate hyperintensity on T2WI or DWI; b)
nodular arterial enhancement without washout during
portal venous and equilibrium/late phases; c) nodular
arterial enhancement and isointensity during the hepa-
tobiliary phase; and d) lesions showing hyperintensity
compared to surrounding liver parenchyma during the
hepatobiliary phase and on T2WI or DWI. Meanwhile,
the following criteria were used to diagnose benign
lesions (hemangioma or A-P shunt): 1) peripheral nodu-
lar or global enhancement during arterial phase and
prolonged enhancement during portal venous and/or
equilibrium/late phases, and 2) wedged-shaped arterial
enhancement located at the peripheral liver with/with-
out early delineation of peripheral portal branches and
isoattenuation or isointensity during portal venous,
equilibrium/late, or hepatobiliary phases.
First, each reader recorded the size (defined as the
maximum diameter), the segmental location according
to the Couinaud classification, and the attenuation or
intensity on precontrast images of each lesion. Then
the readers recorded the attenuation or intensity com-
pared to surrounding liver parenchyma of each lesion
during arterial, portal venous, equilibrium/late, and
hepatobiliary phases.
Finally, based on the above-mentioned criteria, each
reader classified each lesion using the following five-
point confidence scale: score 1, no HCC; score 2, prob-
ably no HCC; score 3, intermediate; score 4, probably
HCC; score 5, definite HCC. In patients with multiple
lesions, in addition to the descriptions of size and seg-
mental location of the lesions, the readers drew arrows
with numbers for all lesions that were evaluated, which
were saved as digital images in the workstation to
avoid a mismatch between lesions identified with
MDCT, MRI, and the reference standard.
Statistical Analysis
Receiver operating characteristics (ROC) analysis was
performed to evaluate the diagnostic performance of
the three sets of images (MDCT, dynamic MRI, and
combined MRI) in the diagnosis of HCC for each
reader. Areas under the empiric ROC curves (Az val-
ues) were estimated nonparametrically and compared
between the three sets of images. Subsequently, sen-
sitivity and specificity were calculated for each set of
images. To that end, confidence scores of 1–3 were
considered negative for HCC, whereas confidence
scores of 4 and 5 were regarded as positive for HCC.
Differences in sensitivity and specificity between the
three sets of images were assessed using the McNe-
mar test. All analyses were done for both observers
separately. Reader agreement at MDCT, dynamic MRI,
and combined MRI was analyzed using the weighted k
statistic, defined as poor (<0.2), fair (>0.2 to 0.4),
moderate (>0.4 to 0.6), good (>0.6 to 0.8), and
excellent (>0.8 to 1) agreement. P < 0.0166 was
considered to indicate a statistically significant differ-
ence because we employed Bonferroni correction for
comparing the results among the three groups. All
analyses were performed using commercial statistical
software (JMP, v. 8; SAS Institute Japan, Tokyo,
Japan).
RESULTS
ROC Analysis
Az values for the diagnosis of HCC of each set of
images for both readers are shown in Table 2. The
two readers had comparable (not significantly differ-
ent) Az values for all lesions between MDCT (0.921 for
reader 1, and 0.917 for reader 2) and dynamic MRI
(0.925 for reader 1, and 0.935 for reader 2). However,
both readers achieved significantly higher Az values
for all lesions with combined MRI (0.961 for reader 1,
and 0.967 for reader 2) than with dynamic MRI (P ¼
0.0083 for reader 1, and P ¼ 0.0162 for reader 2). In
addition, for smaller lesions (<1.5 cm) the Az value
with combined MRI was significantly higher than that
with MDCT for both readers (P ¼ 0.0027 for readers 1
Table 2
Az values of each set of images in the diagnosis of HCC for the
two readers
MDCT
Dynamic
MRI
Combined
MRI
All lesion (n ¼ 60)
Reader 1 0.921 0.925 0.961y
Reader 2 0.917 0.935 0.967y
Mean 0.919 0.930 0.964
Lesion <1.5 cm (n ¼ 16)
Reader 1 0.765 0.890 0.952*
Reader 2 0.765 0.858 0.952*
Mean 0.765 0.874 0.952
Note: Combined MRI: dynamic MRI þ hepatobiliary phase MR
images.
yThere was a significant differences in Az values between dynamic
MRI and combined MRI for both readers (p < 0.0166: p ¼ 0.0083
for reader 1, p ¼ 0.0162 for reader 2).
*There was a significant difference in Az values between MDCT
and combined MRI for both readers (P < 0.0166: p ¼ 0.0027 for
reader 1, 0.0027 for reader 2).
There were no significant differences in Az values between MDCT
and dynamic MRI for both readers.
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and 2) (Fig. 1). Reader agreement for the diagnosis of
HCC using MDCT, dynamic MRI, and combined MRI
was good to excellent, given the k values of 0.921
(95% confidence interval [CI]: 0.881–0.961), 0.921
(95% CI: 0.882–0.960), and 0.789 (95% CI: 0.727–
0.850), respectively.
Sensitivity and Specificity
Sensitivities and specificities of each set of images for
both readers are shown in Table 3. The sensitivities
for all lesions increased with the additional interpreta-
tion of hepatobiliary phase images (combined MRI)
from 75.0% to 86.7% and from 78.3% to 86.7% for
readers 1 and 2, respectively, and the significant dif-
ferences were achieved between it and MDCT (P ¼
0.0045 for reader 1, P ¼ 0.0126 for reader 2) for both
readers and were also observed between it and
dynamic MRI (P ¼ 0.0082) for reader 1. The sensitiv-
ities for smaller lesions (<1.5 cm) with combined MRI
were significantly higher than those with MDCT (P ¼
0.0143 for reader 1, and P ¼ 0.0143 for reader 2) for
Figure 1. A 55-year-old man
with a history of hepatitis C
cirrhosis (Child-Pugh A) and
biopsy-proven moderately dif-
ferentiated HCC. (a) MDCT
and (d) EOB-enhanced arte-
rial phase MR image demon-
strate a hypervascular nodule
at segment VI–VII. In (e,f)
EOB MR images obtained
during portal venous and
equilibrium/late phases, rapid
washout (arrows) is seen,
although this finding is unclear
in (b,c) MDCT images obtained
during portal venous and equi-
librium phases. In (g) the Gd-
EOB-enhanced hepatobiliary
phase MR image at 20 minutes,
the nodule is clearly hypo-
intense (arrow) compared to
surrounding liver parenchyma.
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both readers, although there were no significant dif-
ferences between dynamic MRI and combined MRI.
Meanwhile, the specificities of all imaging modalities
were higher (about 90%) without any significant dif-
ferences among the three sets of images sets for both
readers.
False-Negative Nodules
Among all HCCs, 53 (88.3%) HCCs were hypointense
in the hepatobiliary phase, whereas five (8.3%) and two
(3.3%) were hyperintense and isointense, respectively.
CT and MR findings of false-negative nodules with a
score of 1 or 2 are summarized in Table 4. The number
of false-negative nodules on MDCT for readers 1 and 2
were both 14, and those on dynamic MRI were 11 and
10, respectively. The majority of these nodules (75%
and 62% for MDCT and dynamic MRI, respectively)
were mischaracterized due to a lack of identification of
washout findings, although arterial enhancement could
be identified (Figs. 1, 2). Among these nodules, five
nodules (45.5%, 5/11) for reader 1 and five (50.0%, 5/
10) for reader 2 showed hypointensity to surrounding
liver parenchyma during hepatobiliary phases (Fig. 2).
On the other hand, four nodules became hyperintense
to surrounding liver parenchyma during hepatobiliary
phases because of uptake of the contrast into the HCC.
Only one nodule which was missed with both dynamic
and combined MRI was correctly judged as HCC on
MDCT by both readers. Meanwhile, the two false-nega-
tive nodules, which did not show any arterial enhance-
ment on both MDCT and dynamic MRI were hypoin-
tense (n ¼ 2) during hepatobiliary phase images. The
pathological examination proved that all these nodules
were well-differentiated HCCs.
False-Positive Lesions
Both readers recorded one false-positive nodule for
MDCT, two for dynamic MRI, and three for combined
MRI. The false-positive CT findings were attributed to
A-P shunts (10 mm in size). The false-positive MR
findings were attributable to one high-flow hemangi-
oma and two A-P shunts, which showed hypointensity
to surrounding liver parenchyma during equilibrium
and hepatobiliary phases (Fig. 3).
DISCUSSION
The results of our study demonstrate that the accu-
racy of dynamic EOB-enhanced MRI for the diagnosis
of early stage HCC is equivalent to that of MDCT,
Table 3
Sensitivity and specificity of each set of images in the diagnosis of HCC for each reader
MDCT
Dynamic
MRI
Combined
MRI
All lesions (n ¼ 60)
Reader 1
Sensitivity 68.3 (41/60) 75.0 (45/60) 86.7 (52/60)*,y
Specificity 94.9 (37/39) 92.3 (36/39) 89.7 (35/39)
Reader 2
Sensitivity 71.7 (43/60) 78.3 (47/60) 86.7 (52/60)*
Specificity 94.9 (37/39) 94.9 (37/39) 92.3 (36/39)
Lesion <1.5 cm (n ¼ 16)
Reader 1
Sensitivity 56.3 (9/16) 81.3 (13/16) 93.8 (15/16)*
Specificity 96.7 (29/30) 96.7 (29/30) 96.7 (29/30)
Reader 2
Sensitivity 56.3 (9/16) 75.0 (12/16) 93.8 (15/16)*
Specificity 96.7 (29/30) 96.7 (29/30) 96.7 (29/30)
Note: Combined MRI: dynamic MRI þ hepatobiliary phase MR images.
Data are percentages with numbers used to calculate percentages in parentheses.
*There was a significant difference in sensitivities between MDCT and combined MRI for both readers (All lesions: p ¼ 0.00045 for reader
1, p ¼ 0.0126 for reader 2; Lesion < 1.5 cm: p ¼ 0.0143 for reader 1, p ¼ 0.0143 for reader 2).
yThere was a significant difference in sensitivities between dynamic MRI and combined MRI for reader 1 (p ¼ 0.0082) Specificities
between the three sets of images were not significantly different.
Table 4
Characteristics of false negative nodules with a score of 1 and 2
on dynamic MDCT and MRI, and signal intensity on hepatobiliary
phase images, for each reader
MDCT
MRI
Set 1
SI on
HB phase
Reader 1 n ¼ 14 n ¼ 11
A.E. (þ)/Washout () 11(78.6) 7(63.6) low 3
high 3
iso 1
A.E. ()/Washout (þ) 2 (14.3) 1 (9.1) low 1
A.E. ()/Washout () 1 (7.1) 3 (27.3) low 1
high 1
iso 1
Reader 2 n ¼ 14 n ¼ 10
A.E. (þ)/Washout () 10 (71.4) 6 (60.0) low 3
high 3
iso 0
A.E. ()/Washout (þ) 2 (14.3) 1 (10.0) low 1
A.E. ()/Washout () 2 (14.3) 3 (30.0) low 1
iso 1 high 2
Note: MRI Set 1: Dynamic MR images alone, MRI Set 2: Com-
bined dynamic and hepatobiliary phase MR images.
Abbreviations: A.E., arterial enhancement; SI, signal intensity; HB,
hepatobiliary phase Data are absolute numbers with percentages
in parentheses.
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whereas the combined interpretation of dynamic and
hepatobiliary phase images significantly improves
sensitivity and accuracy for the diagnosis of lesions
less than 1.5 cm in diameter, compared with either
dynamic EOB-enhanced MRI or triple-phase dynamic
MDCT.
Although the total amount of gadolinium of EOB
(concentration; 0.25 mmol/mL, administration vol-
ume; 0.1 mL/kg) is one-quarter of that of other,
standard gadolinium chelate agents (concentration;
0.5 mmol/mL, administration volume; 0.2 mL/kg), in
this study we found comparable arterial phase results
in hypervascular HCCs with Gd-EOB-DTPA and
MDCT as previously reported (21,22). The number of
missed HCC nodules (n ¼ 1 for both readers) with
dynamic EOB-enhanced MRI in the arterial phase
was almost equal to that with MDCT (n ¼ 2 for both
readers). Compared to the T1 relaxivity of standard
gadolinium chelate agents in blood (about 4.5
Lmmmol1s1), the relaxivity of EOB (8.2
Lmmmol1s1) is increased in human blood by the
extent of protein binding (10.7%), which is higher
than that of standard gadolinium chelate agents
(1.6%). Thus, its higher T1 relaxivity can compensate
for the lower amount of gadolinium. In addition to the
characteristic molecular action of EOB, other factors
supporting the better results with EOB are essential.
As described, the bolus administration volume with
EOB is only half of standard gadolinium chelate
agents. Therefore, more exact scan timing for arterial
phase imaging is needed to achieve the potential abil-
ity of EOB. We used the MR fluoroscopic bolus detec-
tion technique (CARE Bolus) for this purpose in this
study. Additionally, we selected a relatively slow injec-
tion rate (1 mL/sec) to reduce artifacts and accelerate
protein binding of EOB in human blood because a
faster injection rate may induce signal inhomogene-
ities in k-space, causing ringing artifacts (20). The use
of recently developed high-resolution 3D-GRE sequen-
ces with fat saturation (VIBE) also provides higher
liver-lesion contrast, as researchers have described
previously (23).
Thanks to recent advances in hardware, improve-
ments in spatial resolution, and contrast injection
methods, the sensitivities of dynamic MDCT and MRI
with nonspecific extracellular agents for the diagnosis
of HCC appear to have increased (24). However, the
diagnosis of small HCC is still challenging because of
variable vascular characteristics of HCCs. In the pres-
ent study the majority of false-negative nodules on
MDCT and dynamic EOB-enhanced MRI (75% and
62% for MDCT and dynamic MRI, respectively) were
due to a lack of identification of washout findings,
although arterial enhancement could be identified.
The identification of washout findings in the portal ve-
nous or late phase is crucial for a reliable diagnosis of
HCC, especially for the differentiation from nonneo-
plastic early arterial enhancement (focal A-P shunt).
Figure 2. A 70-year-old man with a history of hepatitis C cirrhosis (Child-Pugh B) and biopsy-proven moderately differenti-
ated HCC. Gd-EOB-enhanced arterial phase MR image shows a hypervascular nodule (arrow) at segment VIII (hepatic dome).
Small A-P shunt (arrowhead) near the lesion is also seen on the Gd-EOB-enhanced arterial phase MR image. b,c: In Gd-
EOB-enhanced portal venous and late phases MR images, the washout finding is unclear, with a score of 3 assigned by both
readers. On the other hand, (d) the Gd-EOB-enhanced hepatobiliary phase MR image at 20 minutes clearly shows a hypoin-
tense nodule (arrow) at segment VIII (hepatic dome). Both readers judged this nodule as HCC (score of 5).
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Although the identification rate of arterial enhance-
ment of the tumors on both MDCT and MRI is mainly
influenced by the contrast injection and acquisition
methods, that of the washout finding is mainly deter-
mined by the histopathological characteristics of
HCCs, which are also linked to their tumor sizes.
As recent researchers reported, the MR images in
the hepatobiliary phase with EOB contribute to
improvement of tumor detection and characterization
(10,13–18). Usually, the majority of hypervascular
HCCs appear hypointense (88.3% in this study) in the
hepatobiliary phase due to lack of normal hepatocytes
in the tumor (9,21). In present study, among all false-
negative nodules on dynamic MRI, five nodules
(45.5% for reader 1 and 50.0% for reader 2) showed
hypointensity to surrounding liver parenchyma during
the hepatobiliary phase, and this additional informa-
tion could improve the diagnosis of HCC. Moreover,
the sensitivity and accuracy for the diagnosis of
lesions less than 1.5 cm in diameter with combined
Figure 3. A 67-year-old man with a
history of chronic hepatitis C with focal
A-P shunt. Gd-EOB-enhanced arterial
phase MR image shows a hypervascu-
lar nodule (arrow) at segment VIII. In
(b) the Gd-EOB-enhanced portal ve-
nous phase MR image, the nodule is
isointense to surrounding liver paren-
chyma. In (c,d) Gd-EOB-enhanced late
and hepatobiliary phases MR images at
20 minutes, the nodule (arrows) is
faintly hypointense to surrounding liver
parenchyma with a score of 4 assigned
by both readers. Also note a hypoin-
tense tiny cyst (arrowhead) near this
nodule at segment IV on the hepatobili-
ary phase image at 20 minutes. In (e)
the T2-weighted image, the nodule is
not visible.
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MRI were also significantly higher than those of triple-
phase dynamic MDCT. Therefore, added interpreta-
tions of hepatobiliary phase images could significantly
improve the diagnosis of HCC, in particular in small
lesions showing isointensity during portal venous or
equilibrium phases, which could be difficult to differ-
entiate from nonneoplastic early arterial enhancement
(focal A-P shunt). Moreover, EOB-enhanced MRI may
allow for the demonstration of minimal dedifferenti-
ated hepatocytes within the tumors prior to changes
of tumor vascularity.
Meanwhile, the diagnosis of HCCs showing para-
doxical uptake of EOB, ie, those appearing isointense
or hyperintense compared to surrounding liver paren-
chyma, may be problem. In the present study, 11.6%
of 60 HCCs exhibited hyperintensity (8.3%) or isoin-
tensity (3.3%) compared to surrounding liver paren-
chyma on hepatobiliary phase images. Some investi-
gators have indicated that some well- or moderately
differentiated HCCs may exhibit hyperintensity or iso-
intensity on hepatobiliary images, while some
researchers and our experience indicate that cirrho-
sis-related benign nodules (eg, large regenerative or
dysplastic nodules) may have the same signal on hep-
atobiliary phase images (25). Overlapping findings
between HCC and cirrhosis-related benign nodules
were observed, although lesions showing hyperinten-
sity on T2WI or DWI may be suggested in the diagno-
sis of HCC. Further research is needed to determine
confident imaging criteria for the diagnosis of theses
HCCs.
In this study, both readers recorded one false-posi-
tive nodule on MDCT, two on dynamic MRI, and three
on combined MRI. The false-positive CT findings were
attributed to A-P shunts. The false-positive MR find-
ings were attributed to one high-flow hemangioma
and two A-P shunts (Fig. 3). As previous investigators
have indicated, high-flow hemangioma may show rela-
tive hypointensity compared to surrounding liver pa-
renchyma during equilibrium or hepatobiliary phases,
which is called the ‘‘pseudo washout’’ sign (26). The
period in which EOB acts as an extracellular agent is
shorter than other contrast agents and it is quite rap-
idly taken up in the normal functioning liver. There-
fore, in some high-flow hemangiomas the characteris-
tic prolonged enhancement might be diminished
during equilibrium or hepatobiliary phases, which
could thus mimic hypervascular HCCs. Nevertheless,
the presence of high signal intensity on T2WI for he-
mangioma may be helpful for differentiating high-flow
hemangiomas from hypervascular HCCs.
In line with previous reports, the remaining false-
positive nodules on MDCT and Gd-EOB-DTPA
enhanced MRI were attributed to A-P shunts (13).
Although A-P shunts usually exhibit a signal intensity
identical to that of surrounding liver parenchyma on
Gd-EOB-DTPA-enhanced MRI, we found that two A-P
shunts (7.69%, 2/26) showed hypointensity compared
to surrounding liver parenchyma during equilibrium
or hepatobiliary phases, as has also been reported in
a recent study (27).
This study had some limitations. First, our study
was retrospective. Further, prospective research is
needed to confirm our results. Second, we included a
relatively large number of patients with good liver
function, and the number of patients with advanced
or endstage liver cirrhosis, in whom liver enhance-
ment after EOB injection could be worse, was rela-
tively low. This factor could affect our results,
although it should be noted that the diagnosis of HCC
in patients with maintained liver function has more
important therapeutic implications than in those with
a poor liver function. Finally, the benign lesions in
this study included hemangiomas and A-P shunts.
Although these benign liver lesions are common and
their differentiation from hypervascular HCCs is an
important diagnostic issue, no other types of benign
liver lesions were included. Some cirrhotic benign
nodules (eg, regenerative nodules, dysplastic nodules,
or focal nodular hyperplastic areas) could have an
atypical enhancement behavior during dynamic and
hepatobiliary phases, mimicking HCCs. Further
research including a wider spectrum of benign lesions
is needed.
In conclusion, the performance of dynamic EOB-
enhanced MRI for the diagnosis of early stage HCC is
equivalent to that of triple-phase dynamic MDCT. The
diagnostic performance of dynamic EOB-enhanced
MRI can significantly be improved by adding hepato-
biliary phase images, in particular in small lesions
showing isointensity during portal or equilibrium
phases. The sensitivity and accuracy of EOB-
enhanced MRI with hepatobiliary phase imaging were
significantly superior to MDCT for the diagnosis of
lesions less than 1.5 cm in diameter. EOB-enhanced
MRI has the potential to replace dynamic MDCT imag-
ing and could become a promising modality for the
noninvasive management of patients with HCC.
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